- Home
- MBRX vs COCH Comparison
MBRX vs COCH Comparison
Compare MBRX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- COCH
- Stock Information
- Founded
- MBRX 2015
- COCH 1995
- Country
- MBRX United States
- COCH United States
- Employees
- MBRX N/A
- COCH N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- MBRX Health Care
- COCH Finance
- Exchange
- MBRX Nasdaq
- COCH Nasdaq
- Market Cap
- MBRX 23.5M
- COCH 19.2M
- IPO Year
- MBRX 2016
- COCH N/A
- Fundamental
- Price
- MBRX $0.48
- COCH $0.84
- Analyst Decision
- MBRX Strong Buy
- COCH Strong Buy
- Analyst Count
- MBRX 4
- COCH 2
- Target Price
- MBRX $5.00
- COCH $9.25
- AVG Volume (30 Days)
- MBRX 2.4M
- COCH 8.5M
- Earning Date
- MBRX 11-12-2025
- COCH 11-13-2025
- Dividend Yield
- MBRX N/A
- COCH N/A
- EPS Growth
- MBRX N/A
- COCH N/A
- EPS
- MBRX N/A
- COCH N/A
- Revenue
- MBRX N/A
- COCH $222,000.00
- Revenue This Year
- MBRX N/A
- COCH $3.66
- Revenue Next Year
- MBRX N/A
- COCH $31.19
- P/E Ratio
- MBRX N/A
- COCH N/A
- Revenue Growth
- MBRX N/A
- COCH N/A
- 52 Week Low
- MBRX $0.25
- COCH $0.74
- 52 Week High
- MBRX $3.65
- COCH $3.09
- Technical
- Relative Strength Index (RSI)
- MBRX 51.87
- COCH 43.60
- Support Level
- MBRX $0.44
- COCH $0.77
- Resistance Level
- MBRX $0.52
- COCH $0.88
- Average True Range (ATR)
- MBRX 0.04
- COCH 0.11
- MACD
- MBRX -0.00
- COCH 0.01
- Stochastic Oscillator
- MBRX 57.48
- COCH 6.25
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.